Organogenesis develops, manufactures, and commercializes regenerative medicine products based on bioactive and acellular biomaterials for advanced wound care, surgery, and sports medicine. The products are used to promote healing in chronic wounds and tissue defects by supporting the body's natural repair mechanisms. It serves healthcare providers with a range of solutions aimed at improving outcomes for patients with difficult-to-heal conditions.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 100.8 | — | -12.2 | — |
| Q3 2025 | 150.5 | — | 14.5 | — |
| Q4 2025 | 225.1 | — | 35.1 | — |
| Q1 2026 | 36.3 | — | -56.2 | — |
| Q2 2026 | 42.8 | -57.5% | -99.3 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: RideNow Group, Inc. (RDNW), High Tide Inc. (HITI), Vuzix Corporation (VUZI), Motorcar Parts of America, Inc. (MPAA), Spok Holdings, Inc. (SPOK), Keros Therapeutics, Inc. (KROS)